Priscilla Biswas and Alessandro Cozzi-Lepri contributed equally.
Significant link between sCD30 changes and HIV viremia in patients treated with HAART†
Article first published online: 24 OCT 2006
Copyright © 2006 Wiley-Liss, Inc.
Journal of Medical Virology
Volume 78, Issue 12, pages 1513–1519, December 2006
How to Cite
Biswas, P., Cozzi-Lepri, A., Delfanti, F., Galli, A., Colangeli, V., Moioli, M. C., Scarchilli, A., Abrescia, N., Vigevani, G., D'Arminio-Monforte, A., Novati, R. and Lazzarin, A. (2006), Significant link between sCD30 changes and HIV viremia in patients treated with HAART. J. Med. Virol., 78: 1513–1519. doi: 10.1002/jmv.20733
- Issue published online: 24 OCT 2006
- Article first published online: 24 OCT 2006
- Manuscript Accepted: 20 JUN 2006
- National AIDS Program of the Istituto Superiore di Sanità (ISS). Grant Numbers: 40C.15, 40D.15
- National AIDS Program: “Pathogenesis, immunity and vaccine for AIDS” Project
- viral load;
- viral success;
- viral rebound;
- immune activation;
- TNF receptor family;
- antiretroviral therapy
Elevated sCD30 levels were generally associated with poor prognosis in chronic HIV infection prior to the era of highly active antiretroviral therapy (HAART). Little information is available on sCD30 and HIV-1 viremia. In this study, the association between sCD30 and HIV-1 viremia was investigated in HIV-infected patients who underwent HAART. sCD30 was measured in 276 patients prior (T0) and 6 months after HAART (T6). Standard survival analyses were used to evaluate the prognostic value of sCD30 and sCD30 change from baseline to predict the virological response to HAART. Higher levels (>30 U/ml) of sCD30 prior to HAART were associated with relatively higher viremia (P = 0.0001) and tended to be associated with a lower chance of achieving virological success (P = 0.13). The median T6 sCD30 level in patients who concomitantly had viremia >500 copies/ml was higher than the median sCD30 level of those with viremia ≤500 copies/ml (P = 0.002). Conversely, within the patients who achieved viral suppression on HAART, those who had concomitantly a larger reduction in sCD30 subsequently experienced a higher rate of virological failure (P = 0.04). A strong, but complex, link exists between sCD30 levels and HIV viremia in the era of HAART. The change in sCD30 levels from pre-therapy to the date of first viral suppression could be used to identify patients who are more likely to experience later virological rebound among those who achieve initially virological success. J. Med. Virol. 78:1513–1519, 2006. © 2006 Wiley-Liss, Inc.